Downregulation of PPARγ by miR-548d-5p suppresses the adipogenic differentiation of human bone marrow mesenchymal stem cells and enhances their osteogenic potential

Journal of Translational Medicine

Guoqiang Zhao²  Yuebai Li²  Yisheng Wang¹  Junkui Sun¹ 

[1] Department of Orthopaedic Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China;Basic Medical College, Zhengzhou University, Zhengzhou, Henan 450001, China

关键词: Adipogenic differentiation;    Bone marrow mesenchymal stem cells;    Peroxisome proliferator-activated receptor-γ;    miR-548d-5p;   

Others  :  810424
DOI  :  10.1186/1479-5876-12-168

 received in 2014-04-24, accepted in 2014-06-06,  发布年份 2014

【 摘 要 】

Background

Human bone marrow mesenchymal stem cells (hBMSCs) are multipotent cells that can differentiate into a variety of cell types. Elevated expression of peroxisome proliferator-activated receptor-γ (PPARγ) promotes the adipogenic differentiation of hBMSCs, and reduces their osteogenic differentiation. MicroRNAs (miRNAs) have been shown to play important roles in the regulation of hBMSCs differentiation. Because bioinformatic analysis has indicated that PPARγ is a candidate target of miR-548d-5p, the aim of this study was to assess the impact of miR-548d-5p on the dexamethasone-induced adipogenic differentiation of hBMSCs.

Methods

A quantitative RT-PCR (qRT-PCR) assay was used to compare miR-548d-5p expression levels in dexamethasone-induced hBMSCs and uninduced control cells. Oil red O staining, cellular triglyceride (TG) content, and the mRNA and protein levels of PPARγ and CCAAT/enhancer binding protein α (C/EBPα) were used to evaluate the adipogenic differentiation of hBMSCs. Alkaline phosphatase (ALP) activity and levels of osteocalcin (OCN) and Runx2 were used to evaluate the osteogenic potential of hBMSCs.

Results

Compared with untreated cells, miR-548d-5p expression levels were downregulated during dexamethasone-induced adipogenic differentiation of hBMSCs. In contrast to the profuse Oil Red O staining in the cytoplasm of dexamethasone + scrambled miRNA-treated cells, there was limited staining in the cytoplasm of dexamethasone + miR-548d-5p-treated cells, indicating the absence of adipocytes. Moreover, compared with scrambled miRNA-treated cells, treatment with miR-548d-5p suppressed cellular levels of PPARγ and C/EBPα mRNA and protein, and cell TG content (P < 0.05). In contrast, compared with scrambled miRNA-treated cells, cellular levels of OCN and Runx2 mRNA and protein, as well as ALP activity, were significantly higher in miR-548d-5p-treated cells (P < 0.05). Western blot and luciferase reporter assays confirmed that miR-548d-5p directly targeted the 3′-untranslated region of PPARγ.

Conclusions

miR-548d-5p is downregulated during dexamethasone-induced adipogenic differentiation of hBMSCs. By directly targeting and downregulating PPARγ, miR-548d-5p suppresses the dexamethasone-induced adipogenic differentiation of hBMSCs and enhances their osteogenic potential. Our findings suggest that miR-548d-5p has potential in the treatment of corticosteroid-induced osteonecrosis of the femoral head.

【 授权许可】

   
2014 Sun et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Chamberlain G, Fox J, Ashton B, Middleton J: Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features and potential for homing. Stem Cells 2007, 25:2739-2749.
• [2]Fink T, Rasmussen JG, Emmersen J, Pilgaard L, Fahlman A, Brunberg S, Josefsson J, Arnemo JM, Zachar V, Swenson JE, Frobert O: Adipose-derived stem cells from the brown bear (Ursus arctos) spontaneously undergo chondrogenic and osteogenic differentiation in vitro. Stem Cell Res 2011, 7(1):89-95.
• [3]Phinney DG, Prockop DJ: Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair-current views. Stem Cells 2007, 25(11):2896-2902.
• [4]Phimphilai M, Zhao Z, Boules H, Roca H, Franceschi RT: BMP signaling is required for RUNX2-dependent induction of the osteoblast phenotype. J Bone Miner Res 2006, 21:637-646.
• [5]Huang W, Yang S, Shao J, Li YP: Signaling and transcriptional regulation in osteoblast commitment and differentiation. Front Biosci 2007, 12:3068-3092.
• [6]Justesen J, Stenderup K, Ebbesen EN, Mosekilde L, T Steiniche T, Kassem M: Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology 2001, 2:165-171.
• [7]Nuttall ME, Gimble JM: Is there a therapeutic opportunity to either prevent or treat osteopenic disorders by inhibiting marrow adipogenesis. Bone 2000, 27(2):177-184.
• [8]Tan G, Kang PD, Pei FX: Glucocorticoids affect the metabolism of bone marrow stromal cells and lead to osteonecrosis of the femoral head: a review. Chin Med J (Engl) 2012, 125:134-139.
• [9]Yin L, Li YB, Wang YS: Dexamethasone-induced adipogenesis in primary marrow stromal cell cultures: mechanism of steroid-induced osteonecrosis. Chin Med J (Engl) 2006, 119:581-588.
• [10]Li H, Li T, Wang S, Wei J, Fan J, Li J, Han Q, Liao L, Shao C, Zhao RC: miR-17-5p and miR-106a are involved in the balance between osteogenic and adipogenic differentiation of adipose-derived mesenchymal stem cells. Stem Cell Res 2013, 10:313-324.
• [11]Wu Z, Xie Y, Bucher NR, Farmer SR: Conditional ectopic expression of C/EBP beta in NIH-3T3 cells induces PPAR gamma and stimulates adipogenesis. Genes Dev 1995, 9:2350-2363.
• [12]Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM: Transcriptional regulation of adipogenesis. Genes Dev 2000, 14:1293-1307.
• [13]Lowell BB: PPARgamma: an essential regulator of adipogenesis and modulator of fat cell function. Cell 1999, 99(3):239-242.
• [14]Wang YS, Li JF, Liu M, Zhao GQ, Hao LY, Li YB: Inhibition of peroxisome proliferator-activated receptor-γ in steroid-induced adipogenic differentiation of the bone marrow mesenchymal stem cells of rabbit using small interference RNA. Chin Med J (Engl) 2014, 127(1):130-136.
• [15]Liu M, Wang YS, Li YB, Zhao GQ: Construction and identification of the recombinant adenovirus vector carrying a small interfering RNA targeting the peroxisome proliferator-activated receptor-γ. Chin Med J (Engl) 2012, 125:671-675.
• [16]Karp X, Ambros V: Developmental biology Encouraging miRNAs in cell fate signaling. Science 2005, 310:1288-1289.
• [17]He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, Kloos RT, Croce CM, de la Chapelle A: The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci 2005, 02(52):19075-19080.
• [18]Ambros V: The functions of animal microRNAs. Nature 2004, 431:350-355.
• [19]Kim VN, Nam JW: Genomics of microRNA. Trends Genet 2006, 22(3):165-173.
• [20]Kwak PB, Iwasaki S, Tomari Y: The microRNA pathway and cancer. Cancer Sci 2010, 101(11):2309-2315.
• [21]Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116(2):281-297.
• [22]Farazi TA, Spitzer JI, Morozov P, Tuschl T: miRNAs in human cancer. J Pathol 2011, 223(2):102-115.
• [23]Laine SK, Alm JJ, Virtanen SP, Aro HT, Laitala-Leinonen TK: MicroRNAs miR-96, miR-124, and miR-199a regulate gene expression in human bone marrow-derived mesenchymal stem cells. J Cell Biochem 2012, 113:2687-2695.
• [24]Eskildsen T, Taipaleenmaki H, Stenvang J, Abdallah BM, Ditzel N, Nossent AY, Bak M, Kauppinen S, Kassem M: MicroRNA-138 regulates osteogenic differentiation of human stromal (mesenchymal) stem cells in vivo. Proc Natl Acad Sci U S A 2011, 08:6139-6144.
• [25]Huang J, Zhao L, Xing L, Chen D: MicroRNA-204 regulates Runx2 protein expression and mesenchymal progenitor cell differentiation. Stem Cells 2010, 28:357-364.
• [26]Itoh T, Nozawa Y, Akao Y: MiRNA-141 and -200a are involved in bone morphogenetic protein-2-induced mouse pre-osteoblast differentiation by targeting distal-less homeobox 5. J Biol Chem 2009, 284(29):19272-19279.
• [27]Wang Q, Cai J, Cai XH, Chen L: miR-346 Regulates Osteogenic Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells by Targeting the Wnt/b-Catenin Pathway. PLoS One 2013, 8(9):e72266.
• [28]Muruganandan S, Roman AA, Sinal CJ: Adipocyte differentiation of bone marrow-derived mesenchymal stem cells: cross talkwith the osteoblastogenic program. Cell Mol Life Sci 2009, 66(2):236-253.
• [29]Takada I, Kouzmenko AP, Kato S: Wnt and PPARγ signaling in osteoblastogenesis and adipogenesis. Nat Rev Rheumatol 2009, 5:442-447.
• [30]Wu Z, Rosen ED, Brun R, Hauser S, Adelmant G, Troy AE, McKeon C, Darlington GJ, Spiegelman BM: Cross-regulation of C/EBP alpha and PPAR gamma controls the transcriptional pathway of adipogenesis and insulin sensitivity. Mol Cell 1999, 3(2):151-158.
• [31]Komori T: Regulation of osteoblast differentiation by Runx2. Adv Exp Med Biol 2010, 658:43-49.
• [32]Jeon MJ, Kim JA, Kwon SH, Kim SW, Park KS: Activation of peroxisome proliferator activated receptor- gamma inhibits the Runx2- mediated transcription of osteocalcin in osteoblasts. J Biol Chem 2003, 278:23270-23277.
• [33]Salasznyk RM, Klees RF, Boskey A, Plopper GE: Activation of FAK is necessary for the osteogenic differentiation of human mesenchymal stem cells on laminin-5. J Cell Biochem 2007, 100(2):499-514.